Answers are grounded in this paper and cite their sources.
Objective : Psychiatric and neurologic disorders are susceptible to polypharmacy having a higher risk of developing drug-drug interactions. Quetiapine, a frequently used atypical antipsychotic, is extensively metabolized by cytochrome P450 3A4 isoenzyme, while oxcarbazepine, an antiepileptic drug, analog of carbamazepine, is a mild-to-moderate inducer of the same isoenzyme. This study aimed to evaluate the pharmacokinetic interaction between a single dose of quetiapine and multiple doses of oxcarbazepine, as pretreatment, compared to quetiapine single-dose alone in rats. Methods : The in vivo experiment was carried out on two groups consisting of 12 Wistar albino rats each. The control group was given a single oral dose of quetiapine 85 mg/kg. The test group received oxcarbazepine 80 mg/kg/day orally, for 5 days followed by a single dose of quetiapine 85 mg/kg. A validated liquid chromatography with tandem mass spectrometry method was employed to simultaneously measure the plasma concentrations of quetiapine and its active metabolite, norquetiapine. Non-compartmental analysis was used to determine the pharmacokinetic parameters of both quetiapine and norquetiapine. Results : Short-term administration of oxcarbazepine determined a significant increase in the systemic exposure of norquetiapine by increasing its peak plasma concentration and the total area under the concentration-time curve by 88.85% and 5.29-fold. The expected enzyme-inducing properties of oxcarbazepine were not visible on the quetiapine’s pharmacokinetic profile, producing, although statistically insignificant, an increase in its exposure. Conclusions : The present experiment showed that the administration of oxcarbazepine can determine some changes in the pharmacokinetics of quetiapine and norquetiapine in vivo.
No takes yet. Share an insight, caveat, or question.
Ciocotișan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: